The effects of Tamarindus indica L. fruit on overweight and besity

Evaluation the effects of Tamarindus indica L. fruit on body weight, serum lipid profile, and blood pressure among obese and overweight adults

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201608259662N11

Enrollment

Registered

2017-01-15

Start date

2016-05-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity. Morbid obesity

Interventions

Intervention 1: Intervention group: Participants of the case group will be asked not only to follow the prescribed diet but also to consume Tamarindus indica L. Fruit pulp (Available in the Market),

Treatment - Drugs

Intervention group: Participants of the case group will be asked not only to follow the prescribed diet but also to consume Tamarindus indica L. Fruit pulp (Available in the Market), 10 grams, twice

Control group: the second group will be asked to use suitable and usual diet for 6 weeks

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Inclusion criteria: obese and overweight adults (BMI over 25 and less 39.9); subjects aged over 18 years. Exclusion criteria: Individuals with a history of diabetes, cardiovascular disease, liver and kidney as well as pregnancy and breastfeeding; Drugs which increase or body weight or are used to lose weight (orlistat, phentermine, diethylpropion, topiramate, bupropion, metformin, SSRI drugs and herbal medicines on the market) from 2 months before the start of the study; Drugs affecting blood lipid levels include statins, fibrates, sex hormones (estrogen, progestins and birth control pills), beta-blockers, alpha-blocker, corticosteroids, isotretinoin, cyclosporine) from 2 months prior to the study and supplements like fish oil which is effect on blood lipids levels

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
BMI. Timepoint: Before and after 6 weeks. Method of measurement: Meters and weight scales.;Total cholestrol. Timepoint: Before and after 6 weeks. Method of measurement: Parss Azmon KIT/Hitachi Device.;HDL. Timepoint: Before and after 6 weeks. Method of measurement: Parss Azmon KIT / Hitachi Device.;LDL. Timepoint: Before and after 6 weeks. Method of measurement: Parss Azmon KIT/Hitachi Device.;TG. Timepoint: Before and after 6 weeks. Method of measurement: Parss Azmon KIT/Hitachi Device.	—

Measure

Time frame

BMI. Timepoint: Before and after 6 weeks. Method of measurement: Meters and weight scales.;Total cholestrol. Timepoint: Before and after 6 weeks. Method of measurement: Parss Azmon KIT/Hitachi Device.;HDL. Timepoint: Before and after 6 weeks. Method of measurement: Parss Azmon KIT / Hitachi Device.;LDL. Timepoint: Before and after 6 weeks. Method of measurement: Parss Azmon KIT/Hitachi Device.;TG. Timepoint: Before and after 6 weeks. Method of measurement: Parss Azmon KIT/Hitachi Device.

—

Secondary

Measure	Time frame
Blood pressure. Timepoint: Before and after 6 weeks. Method of measurement: Sphygmomanometer.	—

Countries

Iran (Islamic Republic of)

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026